Paper39368808
The promises and potential pitfalls of pharmacokinetic model-based dosing in cellular therapy.
Scordo M. Blood Adv, 2024. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. The promises and potential pitfalls of pharmacokinetic model-based dosing in cellular therapy. Papers, record 39368808. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39368808
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The promises and potential pitfalls of pharmacokinetic model-based dosing in cellular therapy.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References8
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27481448 | Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. | Biol Blood Marrow Transplant | 2016 | https://conductscience.org/library/papers/27481448 | PubMed |
| 2 | 38231085 | Is estimated exposure an accurate surrogate for measured fludarabine levels in patients with CAR T-cell therapy? | Blood Adv | 2024 | https://conductscience.org/library/papers/38231085 | PubMed |
| 3 | 27746112 | Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. | Lancet Haematol | 2016 | https://conductscience.org/library/papers/27746112 | PubMed |
| 4 | 37522731 | Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma. | Blood Adv | 2023 | https://conductscience.org/library/papers/37522731 | PubMed |
| 5 | 30327943 | Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation. | Clin Pharmacokinet | 2019 | https://conductscience.org/library/papers/30327943 | PubMed |
| 6 | 31136799 | Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement. | Biol Blood Marrow Transplant | 2019 | https://conductscience.org/library/papers/31136799 | PubMed |
| 7 | 38191740 | Chimeric antigen receptor T-cell therapy and fludarabine: precision dosing imperatives. | Blood Adv | 2024 | https://conductscience.org/library/papers/38191740 | PubMed |
| 8 | 31324638 | Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes. | Blood Adv | 2019 | https://conductscience.org/library/papers/31324638 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD19 | 930 | PubTator's text mining | https://conductscience.org/library/genes/930 | NCBI Gene |
| CXADRP1 | 653108 | PubTator's text mining | https://conductscience.org/library/genes/653108 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39368808
GET https://conductscience.org/api/papers/v1/39368808/authors